Zymeworks Q2 2024 GAAP EPS $(0.49) Misses $0.07 Estimate, Sales $19.243M Miss $48.860M Estimate
Portfolio Pulse from Benzinga Newsdesk
Zymeworks (NYSE:ZYME) reported Q2 2024 GAAP EPS of $(0.49), missing the analyst estimate of $0.07 by 800%. Sales were $19.243M, missing the $48.860M estimate by 60.62%. Despite the misses, EPS improved by 35.53% and sales increased by 174.82% year-over-year.
August 01, 2024 | 8:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Zymeworks reported Q2 2024 GAAP EPS of $(0.49), missing the analyst estimate of $0.07 by 800%. Sales were $19.243M, missing the $48.860M estimate by 60.62%. Despite the misses, EPS improved by 35.53% and sales increased by 174.82% year-over-year.
Zymeworks' significant misses on both EPS and sales estimates are likely to negatively impact the stock price in the short term. However, the year-over-year improvements in EPS and sales may provide some support, but the immediate reaction is expected to be negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100